StockData
Cumberland Pharmaceuticals Inc logo

Cumberland Pharmaceuticals Inc (CPIX) stock

CPIXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 5/3074% above fair value
$6.63+0.51 (+8.33%)

Close on Nov 12, 2026Market cap $99.34MP/E –Yield –

Earnings

Cumberland Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 2, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
$2.16M
-74.0% on a year earlier
Adjusted EPS, Q3 FY2026
$5.07
-$0.06 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Cumberland Pharmaceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Mar 2, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 10, 2026after the close$2.16M-74.0%$5.07–Release
Q2 FY2026ended Jun 30, 2026Aug 4, 2026during market hours––––Release
Q1 FY2026ended Mar 31, 2026May 5, 2026during market hours$9.10M-22.3%-$0.22-$0.13Release
Q4 FY2025ended Dec 31, 2025Mar 3, 2026during market hours$13.70M+31.7%-$0.09-$0.01Release
Q3 FY2025ended Sep 30, 2025Nov 4, 2025during market hours$8.30M-8.8%-$0.13-$0.06Release
Q2 FY2025ended Jun 30, 2025Aug 5, 2025during market hours$10.80M+9.1%-$0.05$0.02Release
Q1 FY2025ended Mar 31, 2025May 6, 2025during market hours$11.71M+37.8%$0.08$0.16Release
Q4 FY2024ended Dec 31, 2024Mar 4, 2025during market hours$10.40M+11.2%––Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024during market hours$9.10M-9.9%-$0.11-$0.02Release
Q2 FY2024ended Jun 30, 2024Aug 6, 2024during market hours$9.90M-9.2%-$0.08$0.01Release
Q1 FY2024ended Mar 31, 2024May 7, 2024during market hours$8.50M-7.6%-$0.14-$0.05Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Cumberland Pharmaceuticals has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Cumberland Pharmaceuticals puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Cumberland Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

  1. Q3 2026 FINANCIAL RESULTS & COMPANY UPDATE
    Results
  2. COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS
    Results
  3. ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE
    News
  4. Focus on Rare Disease Pipeline
    News
  5. UNAUDITED PRO FORMA FINANCIAL INFORMATION
    News
  6. Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE
    Results
  7. to Integrate Commercial Business with Apotex
    Update
  8. 31.1% FOURTH QUARTER 2025 REVENUE GROWTH
    Results
  9. Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program
    News
  10. Cumberland ended the quarter with approximately $66 million in total assets, $40 million in liabilities and $26 million of shareholders’ equity.
    Results
  11. CUMBERLAND PHARMACEUTICALS ANNOUNCES THE ADDITION OF AN
    News
  12. Cumberland ended the quarter with approximately $68 million in total assets, $40 million in liabilities and $28 million of shareholders’ equity.
    Results
  13. Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025
    Results
  14. at MDA Clinical & Scientific Conference
    News
  15. 11.6% Fourth Quarter 2024 Revenue Growth
    Results

See a number that looks wrong?